Akari Therapeutics PLC (NASDAQ: AKTX) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Akari Therapeutics PLC to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, earnings, valuation, profitability and risk.
Insider & Institutional Ownership
27.0% of Akari Therapeutics PLC shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 61.8% of Akari Therapeutics PLC shares are held by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Akari Therapeutics PLC and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Akari Therapeutics PLC||N/A||-$31.46 million||-23.83|
|Akari Therapeutics PLC Competitors||$263.26 million||$68.25 million||-6.44|
Akari Therapeutics PLC’s competitors have higher revenue and earnings than Akari Therapeutics PLC. Akari Therapeutics PLC is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and price targets for Akari Therapeutics PLC and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Akari Therapeutics PLC||0||1||2||0||2.67|
|Akari Therapeutics PLC Competitors||766||3047||11235||227||2.72|
Akari Therapeutics PLC presently has a consensus price target of $8.75, suggesting a potential upside of 103.96%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.77%. Given Akari Therapeutics PLC’s higher probable upside, equities analysts clearly believe Akari Therapeutics PLC is more favorable than its competitors.
This table compares Akari Therapeutics PLC and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Akari Therapeutics PLC||N/A||-77.39%||-55.94%|
|Akari Therapeutics PLC Competitors||-5,486.48%||-451.59%||-42.57%|
Volatility and Risk
Akari Therapeutics PLC has a beta of -9.19, indicating that its stock price is 1,019% less volatile than the S&P 500. Comparatively, Akari Therapeutics PLC’s competitors have a beta of 6.62, indicating that their average stock price is 562% more volatile than the S&P 500.
Akari Therapeutics PLC competitors beat Akari Therapeutics PLC on 8 of the 12 factors compared.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
What are top analysts saying about Akari Therapeutics PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akari Therapeutics PLC and related companies.